These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 30944164)
1. Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation. Bourke CD; Gough EK; Pimundu G; Shonhai A; Berejena C; Terry L; Baumard L; Choudhry N; Karmali Y; Bwakura-Dangarembizi M; Musiime V; Lutaakome J; Kekitiinwa A; Mutasa K; Szubert AJ; Spyer MJ; Deayton JR; Glass M; Geum HM; Pardieu C; Gibb DM; Klein N; Edens TJ; Walker AS; Manges AR; Prendergast AJ Sci Transl Med; 2019 Apr; 11(486):. PubMed ID: 30944164 [TBL] [Abstract][Full Text] [Related]
2. Strain-level analysis of gut-resident pro-inflammatory viridans group Streptococci suppressed by long-term cotrimoxazole prophylaxis among HIV-positive children in Zimbabwe. Gough EK; Bourke CD; Berejena C; Shonhai A; Bwakura-Dangarembizi M; Prendergast AJ; Manges AR Gut Microbes; 2020 Jul; 11(4):1104-1115. PubMed ID: 32024435 [TBL] [Abstract][Full Text] [Related]
3. Brief Report: Cessation of Long-Term Cotrimoxazole Prophylaxis in HIV-Infected Children Does Not Alter the Carriage of Antimicrobial Resistance Genes. Francis F; Gough EK; Edens TJ; Berejena C; Bwakura-Dangarembizi M; Shonhai A; Nathoo KJ; Glass M; Gibb DM; Prendergast AJ; Manges AR J Acquir Immune Defic Syndr; 2020 Dec; 85(5):601-605. PubMed ID: 32852361 [TBL] [Abstract][Full Text] [Related]
4. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. Mulenga V; Ford D; Walker AS; Mwenya D; Mwansa J; Sinyinza F; Lishimpi K; Nunn A; Gillespie S; Zumla A; Chintu C; Gibb DM; AIDS; 2007 Jan; 21(1):77-84. PubMed ID: 17148971 [TBL] [Abstract][Full Text] [Related]
5. Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Mwenya DM; Charalambous BM; Phillips PP; Mwansa JC; Batt SL; Nunn AJ; Walker S; Gibb DM; Gillespie SH Antimicrob Agents Chemother; 2010 Sep; 54(9):3756-62. PubMed ID: 20585110 [TBL] [Abstract][Full Text] [Related]
6. Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. Ishizaka A; Koga M; Mizutani T; Parbie PK; Prawisuda D; Yusa N; Sedohara A; Kikuchi T; Ikeuchi K; Adachi E; Koibuchi T; Furukawa Y; Tojo A; Imoto S; Suzuki Y; Tsutsumi T; Kiyono H; Matano T; Yotsuyanagi H Microbiol Spectr; 2021 Sep; 9(1):e0070821. PubMed ID: 34378948 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe. Burkhart Colorado AS; Lazzaro A; Neff CP; Nusbacher N; Boyd K; Fiorillo S; Martin C; Siebert JC; Campbell TB; Borok M; Palmer BE; Lozupone C Microbiome; 2024 Feb; 12(1):18. PubMed ID: 38310301 [TBL] [Abstract][Full Text] [Related]
9. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Walker AS; Mulenga V; Ford D; Kabamba D; Sinyinza F; Kankasa C; Chintu C; Gibb DM; Clin Infect Dis; 2007 May; 44(10):1361-7. PubMed ID: 17443476 [TBL] [Abstract][Full Text] [Related]
10. Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy. Kyosiimire-Lugemwa J; Anywaine Z; Abaasa A; Levin J; Gombe B; Musinguzi K; Kaleebu P; Grosskurth H; Munderi P; Pala P J Infect Dis; 2020 Jul; 222(3):381-390. PubMed ID: 31714954 [TBL] [Abstract][Full Text] [Related]
11. Cotrimoxazole Prophylaxis Increases Resistance Gene Prevalence and α-Diversity but Decreases β-Diversity in the Gut Microbiome of Human Immunodeficiency Virus-Exposed, Uninfected Infants. D'Souza AW; Moodley-Govender E; Berla B; Kelkar T; Wang B; Sun X; Daniels B; Coutsoudis A; Trehan I; Dantas G Clin Infect Dis; 2020 Dec; 71(11):2858-2868. PubMed ID: 31832638 [TBL] [Abstract][Full Text] [Related]
12. Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection. Mak G; Zaunders JJ; Bailey M; Seddiki N; Rogers G; Leong L; Phan TG; Kelleher AD; Koelsch KK; Boyd MA; Danta M Front Immunol; 2021; 12():688886. PubMed ID: 34135912 [TBL] [Abstract][Full Text] [Related]
13. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. Pemba L; Charalambous S; von Gottberg A; Magadla B; Moloi V; Seabi O; Wasas A; Klugman KP; Chaisson RE; Fielding K; Churchyard GJ; Grant AD J Infect; 2008 Mar; 56(3):171-8. PubMed ID: 18262281 [TBL] [Abstract][Full Text] [Related]
14. Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance. Munjoma PT; Chandiwana P; Wyss J; Mazhandu AJ; Jordi SBU; Gutsire R; Katsidzira L; Yilmaz B; Misselwitz B; Duri K Front Immunol; 2023; 14():1280262. PubMed ID: 38045684 [TBL] [Abstract][Full Text] [Related]
15. Cotrimoxazole prophylaxis was associated with enteric commensal bacterial resistance among HIV-exposed infants in a randomized controlled trial, Botswana. Powis KM; Souda S; Lockman S; Ajibola G; Bennett K; Leidner J; Hughes MD; Moyo S; van Widenfelt E; Jibril HB; Makhema J; Essex M; Shapiro RL J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29119726 [TBL] [Abstract][Full Text] [Related]
16. Does cotrimoxazole prophylaxis in HIV patients increase the drug resistance of pneumococci? A comparative cross-sectional study in southern Ethiopia. Seid M; Beyene G; Alemu Y; Workalemahu B; Delbo M; Taddesse D; Biresaw G; Manilal A PLoS One; 2020; 15(12):e0243054. PubMed ID: 33284828 [TBL] [Abstract][Full Text] [Related]
17. Antiretroviral treatment is less effective at reducing gut microbiome-associated inflammation and T cell activation in people living with HIV in rural versus urban Zimbabwe. Lazzaro A; Colorado ASB; Neff CP; Nusbacher N; Boyd K; Fiorillo S; Martin C; Siebert J; Campbell T; Borok M; Palmer B; Lozupone C Res Sq; 2023 Aug; ():. PubMed ID: 37693491 [TBL] [Abstract][Full Text] [Related]
18. Estimating the impact of alternative programmatic cotrimoxazole strategies on mortality among children born to mothers with HIV: A modelling study. Mathur S; Smuk M; Evans C; Wedderburn CJ; Gibb DM; Penazzato M; Prendergast AJ PLoS Med; 2024 Feb; 21(2):e1004334. PubMed ID: 38377150 [TBL] [Abstract][Full Text] [Related]
19. Alterations in children's sub-dominant gut microbiota by HIV infection and anti-retroviral therapy. Nguyen QT; Ishizaki A; Bi X; Matsuda K; Nguyen LV; Pham HV; Phan CTT; Phung TTB; Ngo TTT; Nguyen AV; Khu DTK; Ichimura H PLoS One; 2021; 16(10):e0258226. PubMed ID: 34634074 [TBL] [Abstract][Full Text] [Related]
20. Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa. Riitho V; Connon R; Gwela A; Namusanje J; Nhema R; Siika A; Bwakura-Dangarembizi M; Musiime V; Berkley JA; Szubert AJ; Gibb DM; Walker AS; Klein N; Prendergast AJ Nat Commun; 2024 Jun; 15(1):5492. PubMed ID: 38944653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]